Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE9A | O76083 | 20/20 | 1.00 |
| ▸ | PDE1C | Q14123 | 16/20 | 1.00 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.77 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.77 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.77 |
| ▸ | PDE5A | O76074 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15996122 | 1.00 | PDE9A (1.00) | PDE9APDE1CHDAC1HDAC2HDAC6 | |
| SCHEMBL12572133 | 0.98 | PDE9A (0.96) | PDE9APDE1CHDAC1HDAC2HDAC6 | |
| SCHEMBL1716718 | 0.92 | PDE9A (1.00) | PDE9APDE1CHDAC1HDAC2HDAC6 | |
| SCHEMBL1716748 | 0.92 | PDE9A (1.00) | PDE9APDE1CHDAC1HDAC2HDAC6 | |
| SCHEMBL1717165 | 0.92 | PDE9A (0.85) | PDE9APDE1CHDAC1HDAC2HDAC6 | |
| SCHEMBL12572229 | 0.92 | PDE9A (0.85) | PDE9APDE1CHDAC1HDAC2HDAC6 | |
| SCHEMBL12572006 | 0.91 | PDE9A (0.84) | PDE9APDE1CHDAC1HDAC2HDAC6 | |
| SCHEMBL12572058 | 0.91 | PDE9A (0.83) | PDE9APDE1CHDAC1HDAC2HDAC6 | |
| SCHEMBL12572115 | 0.90 | PDE9A (0.82) | PDE9APDE1CHDAC1HDAC2HDAC6 | |
| SCHEMBL19181266 | 0.90 | PDE9A (0.85) | PDE9APDE1CHDAC1HDAC2HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2152712-B1 | AMINO-HETEROCYCLIC COMPOUNDS | PFIZER (US) | 2012-01-11 | — | — | EP | claimed |
| US-7964607-B2 | Pyrazolo[3,4-d]pyrimidine compounds | PFIZER INC. (US) | 2011-06-21 | — | — | US | claimed |
| EP-2152712-A1 | AMINO-HETEROCYCLIC COMPOUNDS | Pfizer Inc. (US) | 2010-02-17 | — | — | EP | claimed |
| US-20090030003-A1 | AMINO-HETEROCYCLIC COMPOUNDS | PFIZER INC | 2009-01-29 | — | — | US | claimed |
| WO-2008139293-A1 | AMINO-HETEROCYCLIC COMPOUNDS | PFIZER INC. (US) | 2008-11-20 | — | — | WO | claimed |
| US-20250360137-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | FREEDOM BIOSCIENCES INC (US) | 2025-11-27 | — | — | US | disclosed |
| EP-4618980-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | Freedom Biosciences, Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| WO-2025043067-A2 | PYRAZOLO[3,4-D]PYRIMIDINONE COMPOUNDS FOR THE TREATMENT OF CHRONIC HEART FAILURE | CARDURION PHARMACEUTICALS, INC. (US) | 2025-02-27 | — | — | WO | disclosed |
| WO-2024107445-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | FREEDOM BIOSCIENCES, INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| EP-2152712-B1 | AMINO-HETEROCYCLIC COMPOUNDS | PFIZER (US) | 2012-01-11 | — | — | EP | disclosed |
| US-7964607-B2 | Pyrazolo[3,4-d]pyrimidine compounds | PFIZER INC. (US) | 2011-06-21 | — | — | US | disclosed |
| US-7964607-B2 | Pyrazolo[3,4-d]pyrimidine compounds | PFIZER INC. (US) | 2011-06-21 | — | — | US | disclosed |
| US-7964607-B2 | Pyrazolo[3,4-d]pyrimidine compounds | PFIZER INC. (US) | 2011-06-21 | — | — | US | disclosed |
| US-20090030003-A1 | AMINO-HETEROCYCLIC COMPOUNDS | PFIZER INC | 2009-01-29 | — | — | US | disclosed |
| US-20090030003-A1 | AMINO-HETEROCYCLIC COMPOUNDS | PFIZER INC | 2009-01-29 | — | — | US | disclosed |
| US-20090030003-A1 | AMINO-HETEROCYCLIC COMPOUNDS | PFIZER INC | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250360137-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | PDE9A, PDE3A, PDE2A | PDE9A 1/4885PDE1C 59/4885HDAC1 1438/4885 |
| US-20090030003-A1 | AMINO-HETEROCYCLIC COMPOUNDS | PDE9A, PDE2A, PDE10A | PDE9A 1/4885PDE1C 29/4885HDAC1 721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.